GlassScriptPhysician profile
Michael Stephen Robichaux
NPI 1003301532
$4,373.84
in general payments reported to CMS, 2019-2025
29 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $722 · 2022: $645 · 2023: $881 · 2024: $896 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,007.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $654.31 | 2021-2025 | |
| Amgen INC. | $517.10 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.62 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $400.44 | 2021-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $359.32 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $288.81 | 2022-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $273.99 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $210.89 | 2021-2024 | Xarelto |
| Pfizer INC. | $164.10 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $148.40 | 2022-2023 | Verquvo |
| Atricure, INC. | $92.86 | 2024-2025 | Synergy Ablation System |
| Novo Nordisk INC | $92.78 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abiomed | $85.90 | 2021-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $83.16 | 2023-2024 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $66.38 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $65.40 | 2025 | Evkeeza |
| Scpharmaceuticals INC. | $63.68 | 2024-2025 | |
| Cvrx, INC. | $56.61 | 2023 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $51.83 | 2025 | Uptravi, Opsynvi |
| Kiniksa Pharmaceuticals International, Plc | $40.41 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $36.85 | 2023-2024 | |
| Boston Scientific Corporation | $36.61 | 2024-2025 | Watchman Flx, General - Vascular Intervention |
| Medtronic, INC. | $35.25 | 2021-2023 | Corevalve Evolut R |
| Abbott Laboratories | $28.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.38 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $19.73 | 2023 | |
| Silk Road Medical, INC. | $15.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.56 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.39 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Robichaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.